The clinical trial environment faced a massive disruption in the wake of COVID-19, the scope of which was both unprecedented and incalculable. Clinical trial operators were in triage mode. There was no tested playbook for a pandemic, no standard operating procedure. And almost everything depended on sites. So how will clinical trial stakeholders continue to adapt in a (post-) pandemic world?
Most Recent Flipbooks
In a recent webinar, Steven Beales, Senior VP, Scientific and Regulatory at WCG, facilitated a conversation with FDA leaders, discussing overreporting SUSARs and the impact on patient safety.
16 industry experts share shifts and trends that will inform clinical research in 2020 and beyond.
From cardiovascular adverse events to complex dosing regimens, oncology trials present unique safety-related considerations.